Related Experiment Videos
Cyclosporin therapy in Mooren's ulcer
The British Journal of Ophthalmology
|June 1, 1987
Summary
Systemic cyclosporine effectively treated severe bilateral Mooren's ulcer resistant to other therapies. This immunosuppressive drug induced remission, offering a new treatment option for this rare autoimmune eye disease.
Area of Science:
- Ophthalmology
- Immunology
- Rheumatology
Background:
- Mooren's ulcer is a rare, potentially blinding autoimmune corneal disease.
- Some cases exhibit severe, chronic courses unresponsive to conventional treatments.
Observation:
- A patient presented with bilateral Mooren's ulcer refractory to topical corticosteroids, silver nitrate, conjunctival resection, and systemic immunosuppressants (corticosteroids, cyclophosphamide, azathioprine).
Findings:
- Systemic cyclosporine (10 mg/kg/day) achieved complete resolution of corneal ulceration within two weeks.
- The patient remained in remission for 15 months under cyclosporine therapy.
- Transient side effects (hirsutism, hypertension, renal and liver function abnormalities) resolved upon dose reduction.
Implications:
- Cyclosporine represents a promising therapeutic option for severe, sight-threatening Mooren's ulcer.
- This case highlights the potential of targeted immunosuppression in managing refractory autoimmune ocular conditions.